Dilafor announces patent grant in the U.S. for its Phase 3 development drug tafoxiparin in priming of labor

STOCKHOLM, SWEDEN – October 3, 2025. Dilafor, today announced it has been granted a U.S. patent protecting the use of its proprietary compound tafoxiparin for the main indication priming of labor. The patent will serve as a key asset as Dilafor advances into phase 3 clinical development of tafoxiparin. The U.S. patent granted by the United States Patent and Trademark Office (USPTO) provides key intellectual property protection in the U.S. for the use of Dilafor’s proprietary development compound tafoxiparin in priming of labor until at least May 2043. Dilafor’s drug candidate tafoxiparin, currently in late-stage development, is ready to advance into Phase 3 clinical trials. Tafoxiparin has a unique mechanism of action that, over the course of few days, prepares both the cervix and the uterus for the onset of labor, thereby increasing the likelihood of a normal vaginal delivery. Currently, more than 30 percent of term pregnant women needs to be initiated into labor. National guidance for labor induction has recently been revised to encourage delivery at 39 weeks of gestation in the US and at 40–41 weeks in Europe. However, existing Standard of Care interventions such as induction therapy, requires surveillance in hospital due to risk for maternal and fetal complications, generating suffering and high healthcare costs. The new guidance will lead to a further increase in the number of deliveries requiring intervention for labor onset. To reduce the constraints at the obstetrical clinics a new, safe home-based treatment option with Dilafor’s development drug for labor priming provides a promising future solution. “The grant of this U.S. patent is a major milestone for Dilafor and is the result of a focused IP strategy to build a comprehensive patent estate around our lead product. This patent will serve as a key asset as we advance the phase 3 clinical development of tafoxiparin, with the mission of supporting pregnant women by enabling priming of labor at home, supporting the natural process leading to the onset of labor”, says Lena Degling Wikingsson, CEO, Dilafor. Dilafor recently announced successful meetings with USFDA and European authorities on the design of the pivotal phase 3 trials. For further information, please contact: Lena Degling Wikingsson, CEO, Dilafor AB Phone: +46 70 790 02 07 TO THE EDITORS About Dilafor AB Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetrical indications. The main owner of Dilafor is KDev Investments AB, which is jointly owned by Karolinska Development AB (publ) and Rosetta Capital IV. The other main owners are Opocrin S.P.A and the Foundation for Baltic and European Studies (Östersjöstiftelsen). For more information, please visit: www.dilafor.com About tafoxiparin Tafoxiparins novel mechanism of action represents a potential breakthrough in obstetrical care by mimicking the natural priming of labor process. The drug candidate uniquely initiates both cervical ripening and myometrial remodeling over several days, initiating an onset of labor leading to a vaginal delivery without traditional mechanical or pharmacological interventions. Tafoxiparin is the first drug developed for self-administration by the mother using a daily autoinjector at home, marking a possible improvement in quality of life for the pregnant woman and her family. Moreover, the tafoxiparin drug candidate has in Phase II studies demonstrated potential to reduce fetal and maternal complications and associated healthcare expenses.

The release as fetched from its publisher. dilafor.com ↗